Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy.

• Tác giả: Claudia Aiello, Sokratis A Apostolidis, Amit Bar-Or, Riley Bove, Julia Davis-Porada, Philip De Jager, Diego A Espinoza, Donna L Farber, Sugeidy Ferreira Brito, Dina Jacobs, Mihir Kakara, Kaho Onomichi, Adelle Ricci, Joseph J Sabatino, Rebecca Straus Farber, Ceren Tozlu, Elizabeth Walker, Sarah Flanagan Wesley, E John Wherry, Zongqi Xia, Lili Zhang, Wen Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 623.818 Design in specific materials
• Thông tin xuất bản: England : NPJ vaccines , 2025
• Bộ sưu tập: NCBI
• ID: 746466

Tóm tắt

Immune-mediated protection generated to COVID-19 mRNA vaccines is associated with anti-Spike (S) protein neutralizing antibodies. However, humoral immunity is compromised in B cell depleting (BCD) therapies, used to treat autoimmune diseases such as Multiple Sclerosis (MS). To study the effect of BCD on the durability and protective efficacy of vaccine-induced immunity, we evaluated S-reactive antibodies and T cell responses 1-70 weeks post-vaccination in MS cohorts treated with BCD compared to non-BCD therapies from four centers. BCD-treated participants had significantly reduced antibody levels and enhanced frequencies of S-reactive CD4